Modulators of the relaxin receptor 1
US-2015119426-A1 · Apr 30, 2015 · US
US10125112B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10125112-B2 |
| Application number | US-201615247438-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 25, 2016 |
| Priority date | May 4, 2012 |
| Publication date | Nov 13, 2018 |
| Grant date | Nov 13, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
Opening claim text (preview).
The invention claimed is: 1. A compound or pharmaceutically acceptable salt thereof having the formula where: R 10 and R 21 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, mono- and di-(C 1 -C 2 alkyl)amino-, a C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy; R 20 is NO 2 , CN, C 2 -C 10 haloalkyl, C 1 -C 10 haloalkoxy, —SR 7 , —SOR 7 , or —SO 2 R 7 , where R 7 is C 1 -C 10 carbhydryl or C 1 -C 10 haloalkyl; and R 3 is cyclohexyl. 2. A method for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1, the method comprising administering to a mammal in need thereof an effective amount of a compound or salt of claim 1 , wherein the facet of mammalian health is heart failure. 3. A compound or salt of the formula wherein R 2 is selected from:
Thiophene-2-carboxylic acid · CPC title
with a four-membered ring · CPC title
having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring · CPC title
Adamantanes · CPC title
linked by a carbon chain containing aromatic rings · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.